NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX). Investors who purchased CARGO securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRGX.
Investigation Details
On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy." The Company continued, "Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the Company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population."
What's Next?
If you are aware of any facts relating to this investigation or purchased CARGO securities, you can assist this investigation by visiting the firm's site: bgandg.com/CRGX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on ACCESS Newswire
